复星医药斯鲁利单抗注射液纳入突破性治疗药物程序

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech Co., Ltd., has received inclusion of its independently developed drug, Surufatinib injection, in the breakthrough therapy designation program for the treatment of gastric cancer in combination with chemotherapy [1] Summary by Relevant Sections - Drug Approval and Indications - Surufatinib injection has been approved for marketing in multiple countries/regions including China, the EU, the UK, Indonesia, Cambodia, Thailand, Malaysia, Singapore, and India [1] - In China, the approved indications include first-line treatment for squamous non-small cell lung cancer, extensive small cell lung cancer, esophageal squamous cell carcinoma, and non-squamous non-small cell lung cancer [1]